The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.

##STR00001##

The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.

##STR00001##

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

A method of converting lignin to phenolic compounds and dicarboxylates in high yield is described. The method involves the use of peroxy acids to react with lignin at a moderated treatment conditions. The peroxy acids can be used along or in combination of other catalysts that have the capability to lower the molecular weight of lignin. A phenolic compounds yield is achieved (>60%) and these phenolic compounds represents high value precursors for various applications include but not limited to antioxidants, health improvement agents, anticorrosive agents, liquid fuel components and performance enhancing agents, resin and adhesives. Dicarboxylic acids can be used for polymer applications or hydrodeoxygenation to hydrocarbon fuel.

A method of converting lignin to phenolic compounds and dicarboxylates in high yield is described. The method involves the use of peroxy acids to react with lignin at a moderated treatment conditions. The peroxy acids can be used along or in combination of other catalysts that have the capability to lower the molecular weight of lignin. A phenolic compounds yield is achieved (>60%) and these phenolic compounds represents high value precursors for various applications include but not limited to antioxidants, health improvement agents, anticorrosive agents, liquid fuel components and performance enhancing agents, resin and adhesives. Dicarboxylic acids can be used for polymer applications or hydrodeoxygenation to hydrocarbon fuel.

The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of Al3818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I. ##STR00001##

The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of Al3818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I. ##STR00001##

The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.

The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.